1ook › Citations

Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha.

Celikel R, McClintock RA, Roberts JR, Mendolicchio GL, Ware J, Varughese KI, Ruggeri ZM
Science 301 218-21 (2003)
Cited: 106 times
EuropePMC logo PMID: 12855810

Abstract

Thrombin bound to platelets contributes to stop bleeding and, in pathological conditions, may cause vascular thrombosis. We have determined the structure of platelet glycoprotein Ibalpha (GpIbalpha) bound to thrombin at 2.3 angstrom resolution and defined two sites in GpIbalpha that bind to exosite II and exosite I of two distinct alpha-thrombin molecules, respectively. GpIbalpha occupancy may be sequential, as the site binding to alpha-thrombin exosite I appears to be cryptic in the unoccupied receptor but exposed when a first thrombin molecule is bound through exosite II. These interactions may modulate alpha-thrombin function by mediating GpIbalpha clustering and cleavage of protease-activated receptors, which promote platelet activation, while limiting fibrinogen clotting through blockade of exosite I.

Reviews - 1ook mentioned but not cited (2)

  1. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Ruggeri ZM, Zarpellon A, Roberts JR, Mc Clintock RA, Jing H, Mendolicchio GL. Thromb Haemost 104 894-902 (2010)
  2. Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands. Troisi R, Balasco N, Autiero I, Vitagliano L, Sica F. Int J Mol Sci 22 (2021)

Articles - 1ook mentioned but not cited (8)

  1. Crystal structure of an RNA aptamer bound to thrombin. Long SB, Long MB, White RR, Sullenger BA. RNA 14 2504-2512 (2008)
  2. Structural basis of regulation of von Willebrand factor binding to glycoprotein Ib. Blenner MA, Dong X, Springer TA. J Biol Chem 289 5565-5579 (2014)
  3. Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. Lancellotti S, Rutella S, De Filippis V, Pozzi N, Rocca B, De Cristofaro R. J Biol Chem 283 30193-30204 (2008)
  4. GpIbα interacts exclusively with exosite II of thrombin. Lechtenberg BC, Freund SM, Huntington JA. J Mol Biol 426 881-893 (2014)
  5. Molecular insight into human platelet antigens: structural and evolutionary conservation analyses offer new perspective to immunogenic disorders. Landau M, Rosenberg N. Transfusion 51 558-569 (2011)
  6. Biophysical investigation of GpIbalpha binding to thrombin anion binding exosite II. Sabo TM, Maurer MC. Biochemistry 48 7110-7122 (2009)
  7. Protein Docking Model Evaluation by Graph Neural Networks. Wang X, Flannery ST, Kihara D. Front Mol Biosci 8 647915 (2021)
  8. In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα. Li BX, Dai X, Xu XR, Adili R, Neves MAD, Lei X, Shen C, Zhu G, Wang Y, Zhou H, Hou Y, Ni T, Pasman Y, Yang Z, Qian F, Zhao Y, Gao Y, Liu J, Teng M, Marshall AH, Cerenzia EG, Li ML, Ni H. Sci Rep 11 11663 (2021)


Reviews citing this publication (36)

  1. Protease-activated receptors in hemostasis, thrombosis and vascular biology. Coughlin SR. J Thromb Haemost 3 1800-1814 (2005)
  2. Protein promiscuity and its implications for biotechnology. Nobeli I, Favia AD, Thornton JM. Nat Biotechnol 27 157-167 (2009)
  3. Platelet physiology and thrombosis. Andrews RK, Berndt MC. Thromb Res 114 447-453 (2004)
  4. Conformational changes associated with protein-protein interactions. Goh CS, Milburn D, Gerstein M. Curr Opin Struct Biol 14 104-109 (2004)
  5. Platelet receptors and signaling in the dynamics of thrombus formation. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Haematologica 94 700-711 (2009)
  6. Thrombin. Di Cera E. Mol Aspects Med 29 203-254 (2008)
  7. Molecular recognition mechanisms of thrombin. Huntington JA. J Thromb Haemost 3 1861-1872 (2005)
  8. Exosites in the substrate specificity of blood coagulation reactions. Bock PE, Panizzi P, Verhamme IM. J Thromb Haemost 5 Suppl 1 81-94 (2007)
  9. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Du X. Curr Opin Hematol 14 262-269 (2007)
  10. New Concepts and Mechanisms of Platelet Activation Signaling. Estevez B, Du X. Physiology (Bethesda) 32 162-177 (2017)
  11. Allosteric disulfide bonds in thrombosis and thrombolysis. Chen VM, Hogg PJ. J Thromb Haemost 4 2533-2541 (2006)
  12. Signalling through the platelet glycoprotein Ib-V-IX complex. Canobbio I, Balduini C, Torti M. Cell Signal 16 1329-1344 (2004)
  13. Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity. Andrews RK, Karunakaran D, Gardiner EE, Berndt MC. Arterioscler Thromb Vasc Biol 27 1511-1520 (2007)
  14. Thrombin-cofactor interactions: structural insights into regulatory mechanisms. Adams TE, Huntington JA. Arterioscler Thromb Vasc Biol 26 1738-1745 (2006)
  15. Structure and interaction modes of thrombin. Bode W. Blood Cells Mol Dis 36 122-130 (2006)
  16. Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. Xu XR, Carrim N, Neves MA, McKeown T, Stratton TW, Coelho RM, Lei X, Chen P, Xu J, Dai X, Li BX, Ni H. Thromb J 14 29 (2016)
  17. The transition of prothrombin to thrombin. Krishnaswamy S. J Thromb Haemost 11 Suppl 1 265-276 (2013)
  18. Pathophysiologic roles of the fibrinogen gamma chain. Farrell DH. Curr Opin Hematol 11 151-155 (2004)
  19. Thrombin domains: structure, function and interaction with platelet receptors. De Cristofaro R, De Candia E. J Thromb Thrombolysis 15 151-163 (2003)
  20. Thrombin as procoagulant and anticoagulant. Di Cera E. J Thromb Haemost 5 Suppl 1 196-202 (2007)
  21. Dysfunctional platelet membrane receptors: from humans to mice. Ware J. Thromb Haemost 92 478-485 (2004)
  22. Thrombin inhibition by the serpins. Huntington JA. J Thromb Haemost 11 Suppl 1 254-264 (2013)
  23. Coagulation Disorders in COVID-19: Role of Toll-like Receptors. Biswas I, Khan GA. J Inflamm Res 13 823-828 (2020)
  24. The interaction of thrombin with blood platelets. Lundblad RL, White GC. Platelets 16 373-385 (2005)
  25. Effects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells. Stouffer GA, Smyth SS. Arterioscler Thromb Vasc Biol 23 1971-1978 (2003)
  26. Thrombin allostery. Di Cera E, Page MJ, Bah A, Bush-Pelc LA, Garvey LC. Phys Chem Chem Phys 9 1291-1306 (2007)
  27. Natural inhibitors of thrombin. Huntington JA. Thromb Haemost 111 583-589 (2014)
  28. Programmed autologous cleavage of platelet receptors. Berndt MC, Karunakaran D, Gardiner EE, Andrews RK. J Thromb Haemost 5 Suppl 1 212-219 (2007)
  29. Harnessing the platelet signaling network to produce an optimal hemostatic response. Brass LF, Tomaiuolo M, Stalker TJ. Hematol Oncol Clin North Am 27 381-409 (2013)
  30. The GPIbalpha-thrombin interaction: far from crystal clear. Vanhoorelbeke K, Ulrichts H, Romijn RA, Huizinga EG, Deckmyn H. Trends Mol Med 10 33-39 (2004)
  31. 14-3-3 proteins in platelet biology and glycoprotein Ib-IX signaling. Chen Y, Ruggeri ZM, Du X. Blood 131 2436-2448 (2018)
  32. Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI. Pathak M, Kaira BG, Slater A, Emsley J. Front Med (Lausanne) 5 66 (2018)
  33. Structure-function of platelet glycoprotein Ib-IX. Quach ME, Li R. J Thromb Haemost 18 3131-3141 (2020)
  34. Designing Smaller, Synthetic, Functional Mimetics of Sulfated Glycosaminoglycans as Allosteric Modulators of Coagulation Factors. Abdelfadiel EI, Gunta R, Villuri BK, Afosah DK, Sankaranarayanan NV, Desai UR. J Med Chem 66 4503-4531 (2023)
  35. Mechanotransduction in skin wound healing and scar formation: Potential therapeutic targets for controlling hypertrophic scarring. Yin J, Zhang S, Yang C, Wang Y, Shi B, Zheng Q, Zeng N, Huang H. Front Immunol 13 1028410 (2022)
  36. The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis. Bendas G, Schlesinger M. Exp Hematol Oncol 11 19 (2022)

Articles citing this publication (60)

  1. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. Matsushima N, Tanaka T, Enkhbayar P, Mikami T, Taga M, Yamada K, Kuroki Y. BMC Genomics 8 124 (2007)
  2. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Proc Natl Acad Sci U S A 103 855-860 (2006)
  3. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, Somers WS, Mosyak L. J Biol Chem 279 23327-23334 (2004)
  4. The structure of the GPIb-filamin A complex. Nakamura F, Pudas R, Heikkinen O, Permi P, Kilpeläinen I, Munday AD, Hartwig JH, Stossel TP, Ylänne J. Blood 107 1925-1932 (2006)
  5. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Lauer A, Cianchetti FA, Van Cott EM, Schlunk F, Schulz E, Pfeilschifter W, Steinmetz H, Schaffer CB, Lo EH, Foerch C. Circulation 124 1654-1662 (2011)
  6. Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse. Welsh JD, Colace TV, Muthard RW, Stalker TJ, Brass LF, Diamond SL. J Thromb Haemost 10 2344-2353 (2012)
  7. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG. J Thromb Haemost 3 742-751 (2005)
  8. Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J, Hofer T, Mage RG, Rader C, Giger RJ. J Neurosci 29 5768-5783 (2009)
  9. Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. Fredenburgh JC, Stafford AR, Leslie BA, Weitz JI. J Biol Chem 283 2470-2477 (2008)
  10. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. Kossmann S, Lagrange J, Jäckel S, Jurk K, Ehlken M, Schönfelder T, Weihert Y, Knorr M, Brandt M, Xia N, Li H, Daiber A, Oelze M, Reinhardt C, Lackner K, Gruber A, Monia B, Karbach SH, Walter U, Ruggeri ZM, Renné T, Ruf W, Münzel T, Wenzel P. Sci Transl Med 9 (2017)
  11. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Nimjee SM, Oney S, Volovyk Z, Bompiani KM, Long SB, Hoffman M, Sullenger BA. RNA 15 2105-2111 (2009)
  12. Quaternary organization of GPIb-IX complex and insights into Bernard-Soulier syndrome revealed by the structures of GPIbβ and a GPIbβ/GPIX chimera. McEwan PA, Yang W, Carr KH, Mo X, Zheng X, Li R, Emsley J. Blood 118 5292-5301 (2011)
  13. Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Berny MA, White TC, Tucker EI, Bush-Pelc LA, Di Cera E, Gruber A, McCarty OJ. Arterioscler Thromb Vasc Biol 28 329-334 (2008)
  14. LRR conservation mapping to predict functional sites within protein leucine-rich repeat domains. Helft L, Reddy V, Chen X, Koller T, Federici L, Fernández-Recio J, Gupta R, Bent A. PLoS One 6 e21614 (2011)
  15. Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94. Chu F, Maynard JC, Chiosis G, Nicchitta CV, Burlingame AL. Protein Sci 15 1260-1269 (2006)
  16. Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Br J Haematol 139 494-503 (2007)
  17. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Kaplan ZS, Zarpellon A, Alwis I, Yuan Y, McFadyen J, Ghasemzadeh M, Schoenwaelder SM, Ruggeri ZM, Jackson SP. Nat Commun 6 7835 (2015)
  18. A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kDa GPIbalpha N-terminal extracellular domain. Ravanat C, Strassel C, Hechler B, Schuhler S, Chicanne G, Payrastre B, Gachet C, Lanza F. Blood 116 1157-1164 (2010)
  19. Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib(alpha) sulfotyrosines through a two-site mechanism involving exosite I. Zarpellon A, Celikel R, Roberts JR, McClintock RA, Mendolicchio GL, Moore KL, Jing H, Varughese KI, Ruggeri ZM. Proc Natl Acad Sci U S A 108 8628-8633 (2011)
  20. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Arthritis Rheum 56 605-613 (2007)
  21. Crystal structure of a platelet-agglutinating factor isolated from the venom of Taiwan habu (Trimeresurus mucrosquamatus). Huang KF, Ko TP, Hung CC, Chu J, Wang AH, Chiou SH. Biochem J 378 399-407 (2004)
  22. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Schulte V, Reusch HP, Pozgajová M, Varga-Szabó D, Gachet C, Nieswandt B. Arterioscler Thromb Vasc Biol 26 1640-1647 (2006)
  23. Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector. Figueiredo AC, de Sanctis D, Gutiérrez-Gallego R, Cereija TB, Macedo-Ribeiro S, Fuentes-Prior P, Pereira PJ. Proc Natl Acad Sci U S A 109 E3649-58 (2012)
  24. Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. Petzold T, Thienel M, Konrad I, Schubert I, Regenauer R, Hoppe B, Lorenz M, Eckart A, Chandraratne S, Lennerz C, Kolb C, Braun D, Jamasbi J, Brandl R, Braun S, Siess W, Schulz C, Massberg S. Sci Transl Med 8 367ra168 (2016)
  25. Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. Hou Y, Carrim N, Wang Y, Gallant RC, Marshall A, Ni H. J Biomed Res 29 (2015)
  26. Structural insights into the inhibition of Wnt signaling by cancer antigen 5T4/Wnt-activated inhibitory factor 1. Zhao Y, Malinauskas T, Harlos K, Jones EY. Structure 22 612-620 (2014)
  27. Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. Weeterings C, Adelmeijer J, Myles T, de Groot PG, Lisman T. Arterioscler Thromb Vasc Biol 26 670-675 (2006)
  28. How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects? Xu G, Ulrichts H, Vauterin S, De Meyer SF, Deckmyn H, Teng M, Niu L. Toxicon 45 561-570 (2005)
  29. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin. Mehta AY, Mohammed BM, Martin EJ, Brophy DF, Gailani D, Desai UR. J Thromb Haemost 14 828-838 (2016)
  30. Thrombin interaction with platelet membrane glycoprotein Ib alpha. Adam F, Bouton MC, Huisse MG, Jandrot-Perrus M. Trends Mol Med 9 461-464 (2003)
  31. Comparative structural analysis of the binding domain of follicle stimulating hormone receptor. Fan QR, Hendrickson WA. Proteins 72 393-401 (2008)
  32. Quantitative analysis and prediction of curvature in leucine-rich repeat proteins. Hindle KL, Bella J, Lovell SC. Proteins 77 342-358 (2009)
  33. Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects. Mehta AY, Thakkar JN, Mohammed BM, Martin EJ, Brophy DF, Kishimoto T, Desai UR. J Med Chem 57 3030-3039 (2014)
  34. Analysis of inter-subunit contacts reveals the structural malleability of extracellular domains in platelet glycoprotein Ib-IX complex. Zhou L, Yang W, Li R. J Thromb Haemost 12 82-89 (2014)
  35. Identification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interaction. Broos K, Trekels M, Jose RA, Demeulemeester J, Vandenbulcke A, Vandeputte N, Venken T, Egle B, De Borggraeve WM, Deckmyn H, De Maeyer M. J Biol Chem 287 9461-9472 (2012)
  36. In vivo relevance for platelet glycoprotein Ibalpha residue Tyr276 in thrombus formation. Guerrero JA, Shafirstein G, Russell S, Varughese KI, Kanaji T, Liu J, Gartner TK, Bäumler W, Jarvis GE, Ware J. J Thromb Haemost 6 684-691 (2008)
  37. Inhibition of thrombin activity by prothrombin activation fragment 1.2. Dasgupta SK, Thiagarajan P. J Thromb Thrombolysis 24 157-162 (2007)
  38. Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran. Nehaj F, Sokol J, Mokan M, Ivankova J, Mokan M. Clin Appl Thromb Hemost 24 268-272 (2018)
  39. Thrombin induces GPIb-IX-mediated fibrin binding to alphaIIbbeta3 in a reconstituted Chinese hamster ovary cell model. Pabón D, Jayo A, Xie J, Lastres P, González-Manchón C. J Thromb Haemost 4 2238-2247 (2006)
  40. Evidence that catalytically-inactivated thrombin forms non-covalently linked dimers that bridge between fibrin/fibrinogen fibers and enhance fibrin polymerization. Mosesson MW, Hernandez I, Siebenlist KR. Biophys Chem 110 93-100 (2004)
  41. First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M. Clin Appl Thromb Hemost 24 914-919 (2018)
  42. Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction. Corral-Rodríguez MÁ, Bock PE, Hernández-Carvajal E, Gutiérrez-Gallego R, Fuentes-Prior P. Blood 117 7164-7173 (2011)
  43. Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates. Tan X, Dey SK, Telmer C, Zhang X, Armitage BA, Bruchez MP. Chembiochem 15 205-208 (2014)
  44. Dabigatran (Pradaxa). Comin J, Kallmes DF. AJNR Am J Neuroradiol 33 426-428 (2012)
  45. Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells. Puhm F, Allaeys I, Lacasse E, Dubuc I, Galipeau Y, Zaid Y, Khalki L, Belleannée C, Durocher Y, Brisson AR, Wolberg AS, Langlois MA, Flamand L, Boilard E. Blood Adv 6 3593-3605 (2022)
  46. Letter The GPIb-thrombin pathway: evidence for a novel role of fibrin in platelet aggregation. Soslau G, Favero M. J Thromb Haemost 2 522-524 (2004)
  47. The role of neuraminidase 1 and 2 in glycoprotein Ibα-mediated integrin αIIbβ3 activation. van der Wal DE, Davis AM, Mach M, Marks DC. Haematologica 105 1081-1094 (2020)
  48. Ecotin modulates thrombin activity through exosite-2 interactions. Castro HC, Monteiro RQ, Assafim M, Loureiro NI, Craik C, Zingali RB. Int J Biochem Cell Biol 38 1893-1900 (2006)
  49. Expression patterns and action analysis of genes associated with blood coagulation responses during rat liver regeneration. Zhao LF, Zhang WM, Xu CS. World J Gastroenterol 12 6842-6849 (2006)
  50. Structural basis of the leukocyte integrin Mac-1 I-domain interactions with the platelet glycoprotein Ib. Morgan J, Saleem M, Ng R, Armstrong C, Wong SS, Caulton SG, Fickling A, Williams HEL, Munday AD, López JA, Searle MS, Emsley J. Blood Adv 3 1450-1459 (2019)
  51. Novel Bernard-Soulier syndrome variants caused by compound heterozygous mutations (case I) or a cytoplasmic tail truncation (case II) of GPIbα. Yamamoto N, Akamatsu N, Sakuraba H, Matsuno K, Hosoya R, Nogami H, Kasahara K, Mitsuyama S, Arai M. Thromb Res 131 e160-7 (2013)
  52. Anti-platelet aggregation of Panax notoginseng triol saponins by regulating GP1BA for ischemic stroke therapy. Xu ZY, Xu Y, Xie XF, Tian Y, Sui JH, Sun Y, Lin DS, Gao X, Peng C, Fan YJ. Chin Med 16 12 (2021)
  53. Antithrombotic effect of SP-8008, a benzoic acid derivative, through the selective inhibition of shear stress-induced platelet aggregation. Ngo T, Kim K, Bian Y, Nam G, Park HJ, Lee K, Cho GS, Ryu JM, Lim KM, Chung JH. Br J Pharmacol 177 929-944 (2020)
  54. Comment New direction for WE thrombin. Berndt MC, Andrews RK. Arterioscler Thromb Vasc Biol 28 205-207 (2008)
  55. Platelet glycoprotein V spatio-temporally controls fibrin formation. Beck S, Öftering P, Li R, Hemmen K, Nagy M, Wang Y, Zarpellon A, Schuhmann MK, Stoll G, Ruggeri ZM, Heinze KG, Heemskerk JWM, Ruf W, Stegner D, Nieswandt B. Nat Cardiovasc Res 2 368-382 (2023)
  56. Platelet ITGA2B inhibits caspase-8 and Rip3/Mlkl-dependent platelet death though PTPN6 during sepsis. Jiang J, Li W, Zhou L, Liu D, Wang Y, An J, Qiao S, Xie Z. iScience 26 107414 (2023)
  57. Editorial Recent advances on GPIb-IX-V complex. Li R. Platelets 33 809-810 (2022)
  58. Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent. Wang J, Gao Y, Chen L, Guo Y, Hu S, Cheng L, Xiao W, Ke J, Zhu Z, Niu L. Blood 137 844-847 (2021)
  59. Thrombin Exosite Maturation and Ligand Binding at ABE II Help Stabilize PAR-Binding Competent Conformation at ABE I. Billur R, Sabo TM, Maurer MC. Biochemistry 58 1048-1060 (2019)
  60. Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice. Kij A, Bar A, Przyborowski K, Proniewski B, Mateuszuk L, Jasztal A, Kieronska-Rudek A, Marczyk B, Matyjaszczyk-Gwarda K, Tworzydlo A, Enggaard C, Hansen PBL, Jensen B, Walczak M, Chlopicki S. Int J Mol Sci 22 (2021)


Quick links